Table 2 Ongoing clinical trials of novel agents in patients with PTCL
Agent | Targeting site | Phase | ClinicalTrial.gov ID |
|---|---|---|---|
Endostar | Angiogenesis inhibitor | II | NCT02520219 |
Selinexor | Selective inhibitor of nuclear export | II | NCT02314247 |
Tipifarnib | Farnesyltransferase inhibitor | II | NCT02464228 |
Darinaparsin | Organic arsenic compound | I | NCT01435863 |
NCT01689220 | |||
Ixazomib | Proteasome inhibitor | II | NCT02158975 |
Denileukin diftitox | Interleukin fusion protein | II | NCT00050999 |
NCT00051012 | |||
Forodesine | PNP inhibitor | I/II | NCT01776411 |
Ruxolitinib | JAK inhibitor | II | NCT01431209 |
Temsirolimus | mTOR inhibitor | I | NCT01614197 |
Carfilzomib | Proteasome inhibitor | I | NCT01336920 |
Panobinostat | Pan-deacetylase inhibitor | II | NCT01261247 |
Clofarabine | DNA synthesis inhibitor | I/II | NCT00644189 |
MK2006 | AKT inhibitor | II | NCT01258998 |
Sorafenib | Multikinase inhibitor | II | NCT00131937 |
Alefacept | Immunosuppressive dimeric fusion protein | I | NCT00438802 |
Pembrolizumab | PD-1 antibody | II | NCT02535247 |